Omega Diagnostics Group PLC Statement re. Government press release
March 15 2021 - 1:28PM
RNS Non-Regulatory
TIDMODX
Omega Diagnostics Group PLC
15 March 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Statement re. Government press release
Omega (AIM: ODX), the medical diagnostics company focused on
CD4, infectious diseases and food intolerance, notes the press
release issued this afternoon by the UK Government announcing its
partnership with British rapid test manufacturers.
Further to the RNS announcement released by Omega this morning
at 7am, the Company is named as one of two British companies to
have secured contracts with the Government to supply rapid lateral
flow tests.
Quote in the press release Colin King, CEO of Omega Diagnostics
Group plc, said:
"We are delighted to deploy our state-of-the-art lateral flow
test production facilities in support of the UK government's
COVID-19 testing programme. The collaboration with other UK-based
IVD companies and DHSC has facilitated the rapid development and
manufacturing capability within the UK. We particularly welcome the
government's assistance to secure the specialist machinery needed
to dramatically increase the scale of our manufacturing capacity
which has allowed us to ensure a ready supply of high quality,
reliable British made rapid lateral flow tests.
"Rapid lateral flow tests are an essential tool for identifying
COVID-19 cases where people have no visible symptoms but could
still be infectious and continue to spread the virus. We are very
proud to be playing our part in the nation's effort to control the
spread of coronavirus by using our production facilities in
Scotland."
The full text of the press release can be seen here:
https://www.gov.uk/government/news/uk-government-announces-partnership-with-british-rapid-test-manufacturers
The following press release was also released in Scotland:
https://www.gov.uk/government/news/uk-government-to-partner-with-clackmannanshire-test-manufacturer
Contacts:
Omega Diagnostics Group PLC www.omegadiagnostics.com
Colin King, Chief Executive via Walbrook PR
Kieron Harbinson, Group Finance
Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUQPWUPGGMA
(END) Dow Jones Newswires
March 15, 2021 13:28 ET (17:28 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024